SAN DIEGO, Nov. 2 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. today announced that the company will be presenting at the Rodman and Renshaw Techvest 7th Annual Healthcare Conference in New York on Wednesday, November 9, 2005.
Jean-Loup Romet-Lemonne, M.D., Chairman and Chief Executive Officer of IDM, will be providing a corporate overview of the company’s product development programs, technologies, strategies and operations. The presentation is scheduled on Wednesday, November 9, 2005 at 10:50 a.m. ET at the Palace Hotel, New York City, in Holmes II.
A live webcast of IDM Pharma’s presentation will be accessible on the company’s Web site at http://www.idm-pharma.com.
About IDM Pharma
IDM Pharma is a biopharmaceutical company focused on the development of innovative products that activate the immune system to treat cancer and infectious disease. IDM is currently developing three types of products: the first is designed to destroy cancer cells by activating innate immunity, the second to prevent tumor recurrence by triggering a specific adaptive immune response, and the third to treat chronic infectious disease with therapeutic vaccines.
IDM Pharma currently has 7 products in clinical development. The most advanced product, Junovan(TM), has completed a Phase III clinical trial in osteosarcoma. Three products are in Phase II clinical trials in bladder cancer, melanoma and non-small cell lung cancer, and three are in Phase I in colorectal cancer, hepatitis B and HIV infection.
IDM Pharma has major product development partnerships with SANOFI-AVENTIS in cancer immunotherapy, and with INNOGENETICS in vaccine development for the treatment of chronic hepatitis B and C and papilloma virus infection. MEDAREX and SANOFI-AVENTIS are corporate partners and shareholders of IDM or its affiliate since 1993 and 2001 respectively.
For more information, visit http://www.idm-pharma.com.
Forward-Looking Statements
This press release includes and the presentation will include forward- looking statements that reflect management’s current views of future events. Actual results may differ materially from the above forward-looking statements due to a number of important factors, including, but not limited to, whether the Company or any of its collaborators will be able to develop pharmaceutical products using the technologies of the Company, risks associated with completing clinical trials of product candidates, risks involved in the regulatory approval process for the Company’s product candidates, the possibility that clinical testing may reveal undesirable and unintended side effects or other characteristics that may prevent or limit the commercial use of proposed products; whether the cash resources of the Company will be sufficient to fund operations as planned; reliance on key employees, especially senior management; the uncertainty of the Company’s future access to capital; the risk that the Company may not secure or maintain relationships with collaborators, and the Company’s dependence on intellectual property. These factors are more fully discussed in the Company’s Annual Report on Form 10-K/A for the year ended December 31, 2004, the Proxy Statement concerning the business combination of Epimmune Inc. and IDM S.A. filed with the Securities and Exchange Commission (SEC) on June 30, 2005, and other periodic reports filed with the SEC. The Company expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.
IDM Pharma, Inc.
CONTACT: Robert De Vaere, Chief Financial Officer of IDM, +1-858-860-2500
Web site: http://www.idm-pharma.com/
